Erick Wayne DeVinney - 16 Mar 2023 Form 4 Insider Report for Axogen, Inc. (AXGN)

Reporting relationship: VP Peripheral Nerve Science
Issuer ticker: AXGN
Reported as of: 16 Mar 2023
Net transaction value: -$22,900
SEC form: 4
Accepted by SEC: 20 Mar 2023, 21:08:45 UTC
Prior SEC filing: 28 Dec 2022
Next SEC filing: 13 Oct 2023
Source filing: View source filing
Reporting owner signature: /s/Erick DeVinney

Key filing fact

Erick Wayne DeVinney filed Form 4 for Axogen, Inc. (AXGN) on 20 Mar 2023.

Key facts

This page summarizes Erick Wayne DeVinney's Form 4 filing for Axogen, Inc. (AXGN).
8 reported transactions and 4 derivative rows are listed below.
Accepted by SEC: 20 Mar 2023, 21:08.

Change

Previous filing in this sequence was filed on 28 Dec 2022.
Current net transaction value: -$22,900.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AXGN transaction

Common Stock

Options Exercise

Transaction value: $0
Shares: +5,900
Change %: +5.5%
Price: $0.000000
Shares after: 112,431
Date: 16 Mar 2023
Ownership: Direct
Footnotes: F1

AXGN transaction

Common Stock

Tax liability

Transaction value: $15,175
Shares: -1,835
Change %: -1.6%
Price: $8.27
Shares after: 110,596
Date: 16 Mar 2023
Ownership: Direct
Footnotes: F2

AXGN transaction

Common Stock

Options Exercise

Transaction value: $0
Shares: +3,000
Change %: +2.7%
Price: $0.000000
Shares after: 113,596
Date: 16 Mar 2023
Ownership: Direct
Footnotes: F1

AXGN transaction

Common Stock

Tax liability

Transaction value: $7,724
Shares: -934
Change %: -0.82%
Price: $8.27
Shares after: 112,662
Date: 16 Mar 2023
Ownership: Direct
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AXGN transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: +5,900
Change %
Price: $0.000000
Shares after: 5,900
Date: 16 Mar 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 5,900
Exercise price
Footnotes: F3, F4

AXGN transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: +3,000
Change %
Price: $0.000000
Shares after: 3,000
Date: 16 Mar 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,000
Exercise price
Footnotes: F3, F5

AXGN transaction Derivative

Employee Stock Option (right to purchase)

Award

Transaction value: $0
Shares: +64,000
Change %
Price: $0.000000
Shares after: 64,000
Date: 16 Mar 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 64,000
Exercise price: $8.27
Footnotes: F6

AXGN transaction Derivative

Restricted Stock Units

Award

Transaction value: $0
Shares: +46,300
Change %
Price: $0.000000
Shares after: 46,300
Date: 16 Mar 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 46,300
Exercise price
Footnotes: F3, F7

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 7 footnotes

Footnote F1

This reflects the number of restricted stock units that became vested as of March 16, 2023.

Footnote F2

Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

Footnote F3

Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

Footnote F4

All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2025 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023, 25% of the aggregate shares vest on March 16, 2024, and 25% of the aggregate shares vest on March 16, 2025. Vested shares will be delivered to the reporting person upon the vesting date.

Footnote F5

All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022, 25% of the aggregate shares vest on March 16, 2023, and 25% of the aggregate shares vest on March 16, 2024. Vested shares will be delivered to the reporting person upon the vesting date.

Footnote F6

All shares of Axogen, Inc. common stock underlying the employee stock option will be fully vested on March 16, 2027 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2025 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter.

Footnote F7

All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2027 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2025 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.